Roswell Park Researchers Identify Immune Biomarker of Response in Patients With Advanced Liver Cancer
August 09, 2019
August 09, 2019
BUFFALO, New York, Aug. 9 -- The Roswell Park Comprehensive Cancer Center issued the following news release:
Roswell Park Comprehensive Cancer Center immunology researchers have uncovered a biomarker that may help explain why some patients respond better than others to a common chemotherapy treatment for liver cancer. They hope that their analysis of immune responses among patients receiving sorafenib can lead to more individualized treatment options and better overall outcomes for . . .
Roswell Park Comprehensive Cancer Center immunology researchers have uncovered a biomarker that may help explain why some patients respond better than others to a common chemotherapy treatment for liver cancer. They hope that their analysis of immune responses among patients receiving sorafenib can lead to more individualized treatment options and better overall outcomes for . . .